FDA Approval is not nearly as expensive as making deals with every local jurisdiction, in every state. Appropriate trials can be done with as few as 526 patients. If you have a science based production or grow facility, it will be less expensive and faster to the shelves.
Yes. Depositing large amounts of cas has always resulted in a Suspicious Activity Report. Since 2014 there has been a special Marijuana-related SARS for state licensed companies. These will not trigger a n account to close unless there are two red flags.
Many advocates and investors hoped that the FDA would reschedule, or maybe de-schedule cannabis in 2018. What happened? Every November the World Health Organization provides a report to the International Organization that makes decisions about risks, both new and updated from past years. The FDA is an important voice in the World Health Organization. In 2017 the FDA requested updated study results from the CBD and cannabis communities. This was a formal indication that scheduling was under review, which had been the case inside the FDA since 2008. Unfortunately, the FDA does not approve of the standard of care being used to verify the molecular contents of cannabis products widely available in state-licensed cannabis businesses. This does not mean that cannabis plants are dangerous. This is a reflection of processing or packaging practices that have been submitted for approval, or lack thereof in this case. The FDA can only reschedule based on applications submitted through the Federal Approval Process. Only in recent years have U.S. businesses been seeking FDA approval, despite the many advantages to the FDA seal of approval.
No. States rights candidates are Republican and, regardless of what President Trump says, Congress writes laws. State representatives would roll back Cannabis to 1970. Democratic candidates universally support legalization and have pushed government agencies to Make FDA approval possible.